# Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019

> **NCT04511650** · PHASE2 · TERMINATED · sponsor: **EyePoint Pharmaceuticals, Inc.** · enrollment: 31 (actual)

## Conditions studied

- COVID-19
- Acute Respiratory Distress Syndrome (ARDS)

## Interventions

- **DRUG:** Razuprotafib Subcutaneous Solution
- **DRUG:** Placebo Subcutaneous Solution

## Key facts

- **NCT ID:** NCT04511650
- **Lead sponsor:** EyePoint Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-21
- **Primary completion:** 2021-02-26
- **Final completion:** 2021-02-26
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** After completion of Step 1 Part 1, the Sponsor discontinued the study based on challenges associated with recruiting and monitoring patients in the current pandemic environment.
- **Last updated:** 2023-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04511650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04511650, "Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04511650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*